Clinical Digest: Recent Clinical Trials on Birth Defects (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Birth Defects. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Birth Defects (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | Design and Application of A Home Care Mini-Program for Children With Congenital Heart Disease After Discharge: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a single-blind, randomized controlled trial aimed at evaluating the effectiveness of a family-centered, WeChat-based home care mini-program for children after congenital heart disease (CHD) surgery. Given the chronic nature of post-operative CHD management and the significant stress placed on families, this study shifts from a deficit-based to a strengths-based perspective, guided by the Double ABC-X model. Children (≤12 years old) who have undergone CHD surgery and their primary caregivers will be recruited. Participants will be randomly assigned to either the intervention group, which uses the mini-program for health education, peer support, and physiological monitoring, or the control group, … |
RUIJIE YANGLAN; | 2026-02-04 |
| 2 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating The Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects. |
CHIA TAI TIANQING PHARMACEUTICAL GROUP | 2026-03-24 |
| 3 | A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial Evaluating The Safety of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This trial employs a single-arm, open-label, multicenter clinical trial design. All study participants who meet the inclusion/exclusion criteria will receive Hydronidone treatment for 4 weeks. The study includes a screening period (up to 21 days) to assess the eligibility of participants. Eligible participants will enter the treatment period and receive Hydronidone capsules at a dosage of 270 mg TID (30 mg/capsule, 3 capsules each time, three times daily, … |
BEIJING CONTINENT PHARMACEUTICAL | 2026-02-18 |
| 4 | A Randomized Clinical Trial to Assess Safety and Efficacy of Allogeneic Adipose-derived Mesenchymal Stem Cells in Promoting The Recovery of Erectile Function Post Radical Retropubic Prostatectomy of Localized Prostate Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer. |
BRIAN MILES; | 2026-03-19 |
| 5 | Workflow Study of The VARIPULSE™ Catheter With The TRUPULSE™ Generator for Treatment of Persistent Atrial Fibrillation (PsAF) With The New VARIPULSE™ Pro Software PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate the workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE catheter and TRUPULSE generator) when used for cardiac ablation with the new VARIPULSE Pro software in participants with persistent atrial fibrillation (PsAF; irregular, rapid heart rhythm that lasts over 7 days and doesn’t stop on its own). |
BIOSENSE WEBSTER | 2026-03-13 |
| 6 | An Open-Label Phase 1b/2a Study to Evaluate The Safety and Tolerability of Oral SVG103 (Paxalisib) in Adults With Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME), Followed By Long-Term Treatment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME. |
SOVARGEN | 2025-12-23 |
| 7 | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on The Efficacy and Safety of Pirfenidone Capsules in The Treatment of Radiation-induced Lung Injury With or Without Immune-related Pneumonia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinical use of immune-checkpoint inhibitors (ICIs) has further increased pulmonary toxicity when radiotherapy (RT) is combined with ICIs. Checkpoint-inhibitor-related pneumonitis (CIP)-i.e., immune-mediated lung injury-may necessitate permanent discontinuation of ICIs, diminish survival benefit, and, in severe cases, … |
MING CHEN; | 2026-02-17 |
| 8 | A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, tolerability, … |
ABBVIE | 2026-03-31 |
| 9 | Effects Of Endometrial Preparation Protocols On Peristalsis And Pregnancy Rates In Frozen Embryo Transfer: A Prospective Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The uterus is a dynamic muscular organ that undergoes rhythmic, wave-like contractions known as endometrial peristalsis or endometrial waves. This muscular activity, which is an essential component of natural fertility, presents a nuanced and sometimes contradictory role in the context of assisted reproductive treatments. Endometrial peristalsis refers to the frequency, amplitude, and pattern of myometrial contractions occurring in different reproductive phases. These peristalsis play vital roles in sperm transport, embryo migration, and implantation. Clinical and imaging studies suggest that abnormal patterns or excessive contractility at the time of embryo transfer may disrupt endometrial-embryo synchrony, impair implantation, … |
LAN N VUONG; | 2026-03-18 |
| 10 | A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate The Safety, Reactogenicity, and Immune Response of The GVGH INTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA). |
GLAXOSMITHKLINE | 2026-01-21 |
| 11 | Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused By Congenital Cytomegalovirus Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Title: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Study 1\. Background and Rationale：Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood neurodevelopmental disability and sensorineural hearing loss (SNHL). International guidelines, based on evidence from high-income countries, recommend a 6-month antiviral course for symptomatic infection. However, clinical practice in China lags significantly, … |
HU BOFEI; | 2026-03-04 |
| 12 | A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral ISM4808 in Healthy Adult Subjects in China PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), food effect, and QTc effects of single and multiple ascending oral doses of ISM4808 in healthy adult subjects. |
GAN ZHOU; | 2026-02-17 |
| 13 | A Phase 2, Multicenter, Open-Label, Single-arm Study to Evaluate The Efficacy and Safety of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes. The study consists of Screening Period (up to 6 weeks), Treatment Period , Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (5 years from the first dose of the study drug or 3 years after the last dose, whichever is longer). Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, … |
TAKEDA | 2026-01-06 |
| 14 | A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants With Generalized Myasthenia Gravis, and B) The Efficacy and Safety of Treatment of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG. |
IMMUNABS | 2026-02-11 |
| 15 | A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy As Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC). The main question it aims to answer is: Does patient with NSCLC in treatment of Nivolumab combined with chemotherapy demonstrate better pCR and PFS ? Is it safe for patient with NSCLC in treatment of Nivolumab combined with chemotherapy ? The data for those participants already receiving nivolumab in combination with chemotherapy as part of their regular medical care for NSCLC will be collected within the designated collection period. |
ONO PHARMACEUTICAL | 2025-09-12 |
| 16 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate The Safety and Immunogenicity of A Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 – 60 years) and elderly (60 – … |
FLORENCIA CAHN; | 2026-02-09 |
| 17 | A Phase 1, First-in-Human Study of A Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-13 |
| 18 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adult Participants With Active Lupus Nephritis Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active Lupus Nephritis (LN). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-02-27 |
| 19 | A Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate The Safety, Tolerability, and Immunogenicity of A Novel Pneumococcal Vaccine in Children PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it. |
MERCK SHARP & DOHME | 2026-04-02 |
| 20 | An Open-label Clinical Trial Investigating The Long-term Safety of Buntanetap in Treating Participants With Parkinson’s Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. |
LAURIE SANDERS; | 2026-03-27 |
| 21 | Efficacy and Safety of Nipocalimab Vs Efgartigimod for Patients With Generalized Myasthenia Gravis in A Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body’s immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-13 |
| 22 | Risk of Serious Adverse Events Following Unsupervised Vs Supervised Rehabilitation After Knee Arthroplasty: Protocol For An Emulated Noninferiority Trial (SAFE-T) PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: SUMMARY Background: After knee arthroplasty (KA), rehabilitation is widely recommended, yet its clinical effectiveness-especially the need for supervision-has been challenged. While some argue that supervised rehabilitation may prevent serious adverse events (SAEs), previous trials show no superiority of rehabilitation, supervised or not, over no rehabilitation in terms of function. However, these trials were underpowered for safety outcomes. A large-scale evaluation is needed to determine if supervision impacts SAE risk, … |
TROELS MARK-CHRISTENSEN; | 2025-07-31 |
| 23 | Intracytoplasmic Sperm Injection (ICSI) Versus Conventional in Vitro Fertilization (IVF) in Couples With Unexplained Infertility: A Multicenter, Open-label, Parallel-group, Randomized Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This multicenter, open-label, parallel-group, randomized controlled trial aims to compare the live birth rate, fertilization outcomes, other pregnancy outcomes and safety between ICSI and conventional IVF among couples with unexplained infertility in China. |
MIN JIN; | 2025-12-19 |
| 24 | A Phase III, Randomized, Double-blind, Multicenter Clinical Study to Evaluate The Efficacy and Safety of SCTB14 Versus Pembrolizumab As First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored. |
SINOCELLTECH | 2026-01-23 |
| 25 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Immunogenicity Characteristics and Preliminary Efficacy of Multiple Ascending Doses of HC022 Injection in Subjects With Systemic Lupus Erythematosus And/or Cutaneous Lupus Erythematosus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this phase Ib study is to evaluate the safety and tolerability of multiple-ascending, subcutaneous (SC) doses of HC022 in SLE/CLE subjects. Secondary objectives of study are as follows: To estimate the PK parameters of multiple-ascending SC doses of HC022 in SLE/CLE subjects；To evaluate the immunogenicity of HC022 administered to SLE/CLE subjects. |
HC BIOPHARMA | 2026-01-28 |
| 26 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate The Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD). |
UCB BIOPHARMA SRL | 2026-03-27 |
| 27 | Efficacy and Safety of IGlarLixi Versus Standard of Care in A Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, … |
SHANGHAI ZHONGSHAN HOSPITAL | 2025-12-29 |
| 28 | A Clinical Study of GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System for The Treatment of Severe, Symptomatic Mitral Regurgitation (MR) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To confirm the effectiveness and safety of the GeminiOne Transcatheter Mitral Valve Repair System for the treatment of severe, symptomatic mitral regurgitation. |
SIERRA VALVE | 2025-07-25 |
| 29 | An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate The Pharmacokinetics of Bimekizumab Administered Intravenously or As A Subcutaneous Injection in Participants With Active Psoriatic Arthritis And/or Active Axial Spondyloarthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration. |
UCB BIOPHARMA SRL | 2026-03-27 |
| 30 | A Phase 1, Randomized, Placebo-Controlled Single Ascending Dose Participant- and Investigator-Blind Study to Investigate The Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants |
UCB BIOPHARMA SRL | 2025-12-23 |
| 31 | Very Low Dose, Add-on Prednisolone in Patients With Newly Diagnosed Rheumatoid Arthritis: A Randomised Placebo-controlled Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Objective To investigate the efficacy of prednisolone 4mg/day added to standard of care in newly diagnosed rheumatoid arthritis (RA) patients with active disease. Hypothesis Add-on prednisolone 4mg/day is efficacious compared to placebo in newly diagnosed RA patients with active disease. Design and subjects This is a 12-week, randomized, placebo-controlled, … |
HO SO; | 2025-12-02 |
| 32 | An Open-Label Study to Investigate The Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-13 |
| 33 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate The Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP). |
UCB BIOPHARMA SRL | 2026-03-16 |
| 34 | A Randomized, Double-Blind, Phase 3 Trial to Investigate The Immunogenicity and Safety of A New Formulation of Tetravalent Dengue Vaccine (TDV) Versus The Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in A Non-Endemic Area for Dengue PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The TDV in current formulation has been approved by health authorities in many countries around the world. The main aim of the study is to confirm that the TDV new formulation induces the similar immune response as approved TDV. Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. Blood samples will be taken before and after the vaccinations. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 5 times. |
TAKEDA | 2026-02-12 |
| 35 | A Retrospective, Observational, and Multicenter Real-world Study on The Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical study is a retrospective, observational, and multicenter post marketing real-world study aimed at evaluating the efficacy and safety of CNCT-19 in the treatment of Chinese adult B-cell acute lymphoblastic leukemia patients. |
JIN WANG; | 2025-12-10 |
| 36 | Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis). In this study, already existing data will be collected from the participant’s medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants. |
MAYA HITES; | 2025-12-16 |
| 37 | A Pilot Study to Assess The Feasibility and Safety of Targeting Mean Arterial Pressure to Reduce Intra-operative Hypotension PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Randomized, multi-site, study assessing the feasibility of lower limit of autoregulation targeted mean arterial pressure (MAP) vs. standard MAP management in neonates undergoing cardiac surgery with cardiopulmonary bypass. After eligibility screening and consent, subjects will be randomized to either the intervention (study) or control group. |
BRADLEY MARINO; | 2025-10-30 |
| 38 | HYMPAVZI S.C. INJECTION 150 Mg Pen SPECIAL INVESTIGATION PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors. |
PFIZER | 2026-03-30 |
| 39 | A Phase 3, Randomized, Controlled, Observer Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety of A Single Dose of GSK’s RSVPreF3 OA Investigational Vaccine in Chinese Adults 18-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed. |
SUWEN LIU; | 2026-03-09 |
| 40 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate The Efficacy, Immunogenicity, and Safety of A Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Aears and Above PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response. |
YANXIA WANG; | 2025-12-09 |
| 41 | An Exploratory Proof of Concept Study to Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) of Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period. |
GALDERMA R&D | 2026-02-23 |
| 42 | A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator’s Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell tells the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery. In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) 2 weeks before surgery. After surgery, … |
ASTELLAS PHARMA GLOBAL DEVELOPMENT | 2026-03-13 |
| 43 | A Randomized, Double-Blind Study to Evaluate The Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, … |
MERCK SHARP & DOHME | 2026-02-27 |
| 44 | A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate The Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn’s Disease PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn’s disease (CD; a long-term condition causing severe inflammation of the intestinal tract). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-12 |
| 45 | A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With An Open Label Study in Adolescents to Evaluate The Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-01-16 |
| 46 | The Effectiveness and Safety of In Vitro Maturation With Fresh Embryo Transfer (The SAIGON Protocol) Versus In Vitro Fertilization With Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Assisted Reproductive Technologies (ART) aim to increase success rates while minimizing patient risks. For women with high AFC or PCOS, conventional IVF carries a high risk of OHSS (Ho et al., 2019). A modern IVF strategy to prevent this uses a GnRH agonist trigger, requiring a freeze-all and subsequent FET (Wong et al., 2017). This reduces OHSS risk but can increase time to pregnancy (Vuong et al., … |
LAN N VUONG; | 2025-10-01 |
| 47 | A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With An ALK Inhibitor PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors are an approved treatment for people with ALK positive NSCLC. Some people stop responding to treatment with ALK inhibitors over time due to more changes happening in their faulty ALK gene, … |
ASTELLAS PHARMA GLOBAL DEVELOPMENT | 2026-03-04 |
| 48 | A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare The Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks. |
WESTVAC BIOPHARMA | 2026-01-30 |
| 49 | LUPKYNIS Drug-use Results Survey PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected. |
OTSUKA PHARMACEUTICAL | 2025-09-19 |
| 50 | Clinical Evaluation of Arrhythmia Mapping With A Paddle-shaped, High-density, Multi-electrode Mapping Catheter PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart. |
BIOSENSE WEBSTER | 2026-02-13 |
| 51 | Cardiopediatric Home Monitoring Tool PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: We hypothesize that a home monitoring program combined with routine postoperative care significantly reduces morbidity and mortality after neonatal and pediatric cardiac surgery. This project differs from the previously published experiences by (a) providing an innovative telemedicine solution via the use of validated measurement sensors, (b) an alert system based on individualized standards, established for each care pathway, and (c) a protocolized response from medical teams in the management of alerts generated by the home monitoring tool. |
NANTES UNIVERSITY HOSPITAL | 2025-09-09 |
| 52 | A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate The Efficacy and Safety of Twice Daily Delgocitinib Cream 20 Mg/g Compared With Cream Vehicle During A 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits. |
LEO PHARMA | 2026-03-16 |
| 53 | Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, … |
NEELKE DE MUNCK; | 2025-09-17 |
| 54 | Intelligence and Neurodevelopmental Outcome After Prenatal Exposure to Labour Epidural Analgesia: A Sibling Matched Clinical Ambidirectional Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: In Belgium, labour epidural analgesia (LEA) has been used for decades in the vast majority of vaginal deliveries (up to 83% of deliveries). Labour epidural analgesia is the most effective and safest way to allow pregnant women a nearly pain-free labour- and birth experience. Recent data showed that the use of LEA was associated with a reduced risk for severe maternal morbidity, neonatal resuscitation and with a reduced risk for low Apgar scores. However, prenatal exposure to labour epidural analgesia has been associated by several study groups with an increased risk for autism spectrum disorder (ASD) in the children, … |
UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN | 2025-06-11 |
| 55 | Congenital and Maternal Point of Care Rapid Testing for Syphilis Study, Uganda PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Syphilis is an infection which affects about 1 in 25 pregnant women in Uganda. If the infection is not diagnosed and treated this can be a risk to the mother and unborn baby’s health. This study aims to see whether a new test for syphilis infection in mothers and babies which can give a result in 10 minutes is as good as the standard tests that are done in the laboratory and take hours or days to provide results. |
ST GEORGE’S UNIVERSITY OF LONDON | 2025-09-15 |
| 56 | Phase II Study to Evaluate The Efficacy and Safety of IBI363 in Combination With IBI305 in Participants With Advanced Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China. Primary endpoint is objective response rate (ORR) per RECIST v1.1. Secondary endpoints include DoR, DCR, TTR, PFS, per RECIST v1.1, and OS; the incidence and severity of AEs, irAEs, SAEs, AESIs and their relationship to the investigational drug, and changes in vital signs, physical examination, and laboratory values before and after study treatment; PK, … |
INNOVENT BIOLOGICS SUZHOU | 2025-08-15 |
| 57 | An Open-Label, Multicenter, Phase Ib/II Clinical Trial of GR1803 Injection in Combination With An Anti-CD38 Monoclonal Antibody Evaluating Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Subjects With Relapsed/Refractory Multiple Myeloma Previously Treated With at Least One Line of Therapy Including Lenalidomide and A Proteasome Inhibitor PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination. |
GENRIX SHANGHAI BIOPHARMACEUTICAL | 2025-07-29 |
| 58 | A Phase Ib/II Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YK012 in The Treatment of Moderate to Severe Systemic Lupus Erythematosus PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE). |
EXCYTE BIOPHARMA | 2026-02-05 |
| 59 | A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate The Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, … |
HOWARD LIEBMAN; | 2026-04-01 |
| 60 | A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate The Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study medicine GSK4527226 is being studied in participants with Alzheimer’s Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study. |
SHEILA BAEZ-TORRES; | 2026-02-02 |
| 61 | The Live Birth Rate Between Single and Multi-step Warming Protocol Applied in Blastocyst Vitrification: A Randomized Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The multi-step thawing protocol with a reduction of non-permeable cryoprotectant concentrations to reduce osmotic shock caused by the rapid influx of water. Recent studies have shown that a simplified warming protocol by only a thawing solution gave a comparable survival rate but increased pregnancy rate, reduced patients’ waiting time, and decreased the workload of embryologists. |
LAN TN VUONG; | 2025-09-12 |
| 62 | A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating The Safety and Efficacy of Guselkumab Administered Subcutaneously in The Treatment of Indian Patients With Psoriatic Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies. |
JOHNSON & JOHNSON PRIVATE | 2026-03-13 |
| 63 | An Open-label, Randomized Controlled Trial of The New One-month Regimen Versus The Current Three-month Regimen for The Treatment of Tuberculosis Infection in Vietnam PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Introduction: Tuberculosis (TB) infection is a key driver of the TB pandemic, with over 10.6 million people fell ill with TB disease in 2022. About one-quarter of the global population is estimated to be infected with TB bacteria. Around 5-10% of people with TB infection will develop active and contagious TB disease, which could be largely avoided if TB infection is identified and given effective preventative treatment, … |
LUONG VAN DINH; | 2025-03-19 |
| 64 | Impact of The Hospital to Home: Optimizing Preterm Infant Environment (H-HOPE) Intervention on Infants With Congenital Defects Requiring Neonatal Surgery and Their Parents PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Infants born with congenital defects may require major surgery in the neonatal period. These infants are at risk for neurodevelopmental impairments. Additionally, their parents are at higher risk for adverse mental health outcomes. Early relationships are essential to healthy growth and development in all children. Relationships between parents and infants born with a congenital defect are negatively impacted by separation due to hospitalization; parental and infant stress exposures; … |
SUSAN HORNER; | 2026-01-28 |
| 65 | An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate The Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors. |
ARRIVENT BIOPHARMA | 2026-02-17 |
| 66 | A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer. In this study, … |
ASTELLAS PHARMA | 2026-03-24 |
| 67 | A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate The Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD. |
TING YANG; | 2025-11-18 |
| 68 | A Phase 3, Randomized, Double-blind, Active-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of HDM1002 Tablets Compared With Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. |
HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL | 2025-07-24 |
| 69 | The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess The Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized By An Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in A Sub Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype. |
SALMAN MUDDASSIR; | 2026-03-03 |
| 70 | A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess The Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina – the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovascular AMD, or both. This study is for people in Japan of 40 years of age or older, … |
ASTELLAS PHARMA | 2026-02-27 |
| 71 | GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy. |
DARRYL LEONG; | 2025-07-29 |
| 72 | PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users): The AstraZeneca Pregnancy Study for Anifrolumab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement. |
ASTRAZENECA | 2026-03-16 |
| 73 | A Phase 2, Open-label, Multi-cohort Study to Assess The Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, … |
ASTELLAS PHARMA GLOBAL DEVELOPMENT | 2026-04-02 |
| 74 | A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate The Safety and Immunogenicity of 2 Doses of A Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within The Routine Vaccination Schedule of Pediatric Participants ≥6 Months to <21 Months of Age PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The purpose of this study is to collect information of vaccination with TDV when given to children younger than 2 years. The main aims of this study are to learn how safe the vaccine is and how well it works to activate a young child’s immune system (this is called immunogenicity). Children between the age of 6 and 21 months will receive two vaccinations with either TDV or placebo 3 months apart. Blood samples will be taken before and after the vaccination as well as throughout the study. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 8 times for vaccinations, blood draws and health checks. |
JORGE ANTONIO PIEDRAHITA OLIER; | 2025-07-15 |
| 75 | An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess The Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram). |
UCB BIOPHARMA SRL | 2026-02-20 |
| 76 | A Phase 4 Single-arm Open-label Study for The Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12. |
AMGEN | 2026-03-25 |
| 77 | A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered As A Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the inclusion of Chinese and Japanese participants in future global studies. |
GLAXOSMITHKLINE | 2025-05-20 |
| 78 | A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs. The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls. |
PFIZER | 2026-03-18 |
| 79 | A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in The Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma. |
RUIHUA XU; | 2026-01-20 |
| 80 | An Open-label, Dose Escalation, Phase I Study to Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced Non-small Cell Lung Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC. Subjects aged ≥19 years with advanced NSCLC with KRAS mutations will be enrolled. Based on the investigator’s judgment of the lung tumor location, RX001 will be administered as a single intratumoral treatment via bronchoscopy or CT-guided percutaneous injection. Additionally, after conducting safety, tolerability, and preliminary anti-tumor efficacy assessments for all subjects up to Week 12 (D84) following IP administration, … |
GENECRAFT | 2025-04-23 |
| 81 | A Single-Arm, Multicenter, Open-Label Clinical Study to Evaluate The Efficacy and Safety of Axicabtagene Ciloleucel Injection As First-Line Therapy of High-Risk Large B-Cell Lymphoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma. |
ZHAO WEILI; | 2025-04-22 |
| 82 | Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D). |
CHIA TAI TIANQING PHARMACEUTICAL GROUP | 2026-01-30 |
| 83 | Immunogenicity of An Intradermal Qdenga Vaccine Among Healthy Volunteers: A Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Official title: Immunogenicity of an intradermal Qdenga vaccine among healthy volunteers: A pilot study |
SARUNYOU CHUSRI; | 2026-01-16 |
| 84 | REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, And/or Outbursts Associated With Dementia Due to Alzheimer’s Disease) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected. |
OTSUKA PHARMACEUTICAL | 2025-07-02 |
| 85 | A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS) |
UCB BIOPHARMA SRL | 2026-03-27 |
| 86 | A Phase II Multicenter, Open-label Study to Evaluate The Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients With Duchenne Muscular Dystrophy (SHIELD DMD) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy. |
HOFFMANN LA ROCHE | 2026-03-27 |
| 87 | Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 Mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. In South Korea, … |
ASTELLAS PHARMA KOREA | 2026-03-11 |
| 88 | CorEvitas Inflammatory Bowel Disease Pregnancy Registry (IBD-PR) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Data collected through the registry may be used to address a range of research questions and objectives, including but not limited to the following: Research question: Is there an increased risk of adverse maternal, fetal, or infant outcomes among individuals who are exposed to Inflammatory Bowel Disease (IBD) treatments during pregnancy? The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy. The secondary objectives of the registry are: To estimate the prevalence of other maternal, fetal, … |
RONNA L CHAN; | 2025-04-04 |
| 89 | A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator’s choice of chemotherapy (ICC). |
DAIICHI SANKYO | 2026-01-12 |
| 90 | Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: A Randomized Double-blind Non-inferiority Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study proposes a planned, double-blind, non-inferiority clinical trial involving patients with febrile neutropenia and risk of extended-spectrum beta-lactamase (ESBL) infection. The goal is: – Analyze the efficacy and tolerability of Ceftolozane/tazobactam (CEF/TAZ) compared to the current standard of care (meropenem) in patients with febrile neutropenia and risk of ESBL infection. Patients will be randomly assigned to receive CEF/TAZ or meropenem, with assessment of clinical response, toxicity and microbiological evolution. Stool samples will be collected before, … |
JOÃO ANTONIO GONÇALVES GARRETA PRATS; | 2025-05-02 |
| 91 | Comparative Study of Tolerance and Immunogenicity Induced By Primary Yellow Fever Vaccination in Pregnant and Non-pregnant Women PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to compare the immunogenicity induced by yellow fever vaccination administered during pregnancy with that induced by vaccination outside pregnancy, and to assess the maternal and fetal tolerance of this vaccination. |
KAOUTAR JIDAR; | 2025-12-15 |
| 92 | Phase 1 Clinical Trial of A Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC. |
WILLIAM GILLANDERS; | 2026-01-13 |
| 93 | The Effect of Vitamin C Supplementation on Assisted Reproductive Pregnancy Outcomes in Patients With Diminished Ovarian Reserve: A Multicenter, Double-blind, Randomized Controlled Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: In the context of the accelerating aging population and the continuous decline in birth rates nationwide, delaying reproductive aging in women and protecting the fertility of women of childbearing age have become urgent issues and key demands that need to be addressed in the field of maternal and child health in China. The ovaries have reproductive and hormone secretion functions and are crucial throughout the female reproductive lifecycle. Women of childbearing age in China face a serious problem of diminished ovarian reserve (DOR), which can lead to infertility, failed in vitro fertilization (IVF) treatments, miscarriage, and other adverse pregnancy outcomes, … |
JIE QIAO; | 2025-06-17 |
| 94 | Randomized, Double-Blind, Placebo-Controlled, Single-Dose, 3-Escalating Cohort, 2 Period Crossover Study Investigating The Tolerability, Safety, and Pharmacokinetics of Ondansetron Inhalation Powder PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if LPI-1503 (Ondansetron Inhalation Powder) can deliver ondansetron into blood through inhalation. It will also learn about the safety of LPI-1503. The main questions it aims to answer are: Does ondansetron enter into blood after inhalation of LPI-1503? And if it does, how efficiently? how rapidly? What medical problems do participants have when and after inhaling LPI-1503? Researchers will compare LPI-1503 to a placebo (a look-alike substance that contains no drug), … |
LUXENA PHARMACEUTICALS | 2026-03-27 |
| 95 | Open-Label, Single-Arm Trial to Evaluate The Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration. |
UCB BIOPHARMA SRL | 2026-02-27 |
| 96 | A Phase I Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YK012 in The Treatment of Primary Membranous Nephropathy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN). |
MINGHUI ZHAO; | 2025-11-17 |
| 97 | Pearls and Pitfalls in Usage of Plasma-Rich Platelet Graft Versus Dartos Flap in Distal Penile Hypospadias Repair PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Hypospadias is the most common congenital anomaly of penis. It is the second most common genital birth defect in boys after cryptorchidism The reinforcement of hypospadias repair with an intermediate layer is believed to reduce the incidence of postoperative complications such as uretherocautanous fistula. Hypospadias is classified by the location of the abnormal urethral meatus into distal penile (glandular ,subcoronal and distal penile), mid penile and proximal penile hypospadias Indeed, uretherocautanous fistula is most common complication after urethroplasty, … |
AHMED ALI AMEN DIAB; | 2025-02-05 |
| 98 | A Phase 3, Open-Label Study to Investigate The Long-Term Safety and Efficacy of LP352 in The Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months. |
LONGBOARD PHARMACEUTICALS | 2026-01-05 |
| 99 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). |
DIANTHUS THERAPEUTICS | 2026-03-27 |
| 100 | A Randomized, Double-Blind, Placebo-Controlled (Participants Aged 18 to 60 Years) and Open-Label (Participants Aged 4 to 17 Years), Phase 2/3 Trial to Evaluate The Immunogenicity and Safety of 2 Doses of A Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Adults, Adolescents, and Children in Japan PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Dengue fever is caused by an infection with the dengue virus. Vaccination with TDV can help prevent dengue fever. The main purpose of this study is to learn about TDV’s ability to create an immune response in adults, adolescents, and children administered. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times. Participants will be in this study for approximately 270 days (9 months). |
TAKEDA | 2025-12-30 |
| 101 | A Phase 1, Open-Label Study to Determine The Biodistribution, Safety, and Tolerability of A Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults Related Papers Related Patents Related Grants Related Experts Highlight: In this study, researchers will learn more about a study drug called BIIB080. BIIB080 is currently a drug under investigation for treatment of Alzheimer’s disease. The main question researchers are trying to answer in this study is how radiolabeled BIIB080 distributes in the brain and spinal cord. To help answer this question, … |
BIOGEN | 2026-03-19 |
| 102 | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, … |
ASTELLAS PHARMA GLOBAL DEVELOPMENT | 2026-03-04 |
| 103 | A Single Arm Phase 4 Trial to Evaluate The Safety and Efficacy of Oral Fruquintinib in The Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion. |
KHALEEL ASHRAF; | 2026-02-27 |
| 104 | A Phase 1b Open-label Study to Investigate Safety, Tolerability and Pharmacokinetics of Intravenous Blinatumomab in Japanese Adult Subjects With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL. |
AMGEN | 2026-01-08 |
| 105 | A Retrospective, Observational Study Using A Healthcare Database to Assess The Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to An Unexposed Control Population PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of the study is to compare the occurrence of major congenital malformations (MCMs) among live births between women with insomnia who are exposed to Dayvigo during the 1st trimester of pregnancy and women with insomnia who are not exposed to any prescription insomnia drugs at any time during the pregnancy and to compare the occurrence of MCMs among live births between women with insomnia who are exposed to Dayvigo during the 1st trimester of pregnancy and women with insomnia who are exposed to a prescription insomnia drug other than Dayvigo during the 1st trimester of pregnancy. |
EISAI | 2025-02-03 |
| 106 | Cera™ ASD Occluder Post-Market Clinical Follow-Up Study：A Multi-Center, Single-arm, Ambispective Post-Market Follow-Up Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this post-market study is to: * collect real-word clinical data and confirm the long-time safety and performance of the Lifetech Cera™ ASD Occluder * identify previously unknown side-effects |
LIFETECH SCIENTIFIC SHENZHEN | 2025-03-06 |
| 107 | Detection of Single Nucleotide Polymorphism (SNP) Rs2235371 of IRF6 Gene in Egyptian Patients with Non-Syndromic Cleft Lip and Palate PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this work is to study the relation between SNP rs2235371 of IRF 6 gene and Non-Syndromic Cleft Lip and Palate in Egyptian Patients in a prospective study |
OMAR ELSHARKAWY; | 2026-02-01 |
| 108 | An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC). |
JANSSEN RESEARCH & DEVELOPMENT | 2025-10-10 |
| 109 | A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas. |
CYTOSINLAB THERAPEUTICS | 2025-05-14 |
| 110 | A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Trial to Evaluate, Tolerability, and Immunogenicity of V540D in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people’s immune system can fight HPV infection and it goes away without treatment. For some people, … |
MERCK SHARP & DOHME | 2026-03-13 |
| 111 | A Randomised, Observer-Blind Trial to Evaluate The Immunogenicity, Safety, and Reactogenicity of A Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose Is Administered Concomitantly With The Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine Is Administered Alone PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs). |
MINERVAX APS | 2025-06-21 |
| 112 | A Randomised, Double Blind, Placebo-controlled, Single Ascending Dose, Phase 1a/1b Multi-centre Study in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease to Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4771261 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it’s safe, what it does to the body, and how the body’s defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD). |
NATHALIE DEMOULIN; | 2025-08-07 |
| 113 | A Single-Center, Randomized, Investigator- and Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics After A Single Dose of Donzakimig in Healthy Chinese and Japanese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants. |
UCB BIOPHARMA SRL | 2026-02-18 |
| 114 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate The Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults. |
MERCK SHARP & DOHME | 2026-02-12 |
| 115 | A Phase 3b, Open Label, Randomized, Standard-of Care Control Arm, Multicenter, Superiority Study Evaluating The Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment. |
SONYA HEATH; | 2026-03-09 |
| 116 | A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Age De-escalation, Dose Combination Ranging Study to Assess The Safety and Immunogenicity of Co-administered Novel Live Attenuated Trivalent Oral Poliomyelitis Vaccine in Healthy Adults, Young Children, and Neonates and Co-administered Novel Live Attenuated Monovalent Oral Poliomyelitis Vaccines 1 and 2 in Neonates in Bangladesh PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main objectives of this study are to : * evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines; * evaluate the safety and tolerability of combined novel oral poliovirus vaccine type 1 (nOPV1) + novel oral poliovirus vaccine type 2 (nOPV2) in neonates, relative to those receiving the bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) control. * compare type-specific cumulative seroconversion rates of poliovirus neutralizing antibody (NAb) titers, among all tnOPV dose combinations, following 4 vaccinations in healthy neonates; … |
K. ZAMAN; | 2025-06-03 |
| 117 | An Open-Label Extension Study to Evaluate The Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants |
UCB BIOPHARMA SRL | 2026-03-27 |
| 118 | A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate The Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans. The study will test single doses of GSK4528287 to check for side effects, measure blood levels, and understand how it works in the body. The study will start with a small dose, and the dose will be increased for each new group of participants. |
MICHALIS S KOSTAPANOS; | 2025-10-29 |
| 119 | The Efficacy of Hydroxychloroquine Combined With Levothyroxine in Euthyroid Women With Thyroid Antibody Positive and Unexplained Recurrent Pregnancy Loss：A Multicenter, Randomized Controlled Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss. Researchers will compare combined treatment of levothyroxine and hydroxychloroquine to a treatment of levothyroxine alone to see if combined treatment works to improve live birth of euthyroid participants with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss. Participants will: * Receive combined treatment of levothyroxine and hydroxychloroquine or treatment of levothyroxine alone every day at least 8 weeks before pregnancy, … |
SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY | 2025-09-23 |
| 120 | A Phase I/II, Single Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate The Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older. |
LILI HUANG; | 2025-06-06 |
| 121 | A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of The Efficacy And. Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for The Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India. |
LEENA DABHI; | 2025-08-07 |
| 122 | A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate The Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people’s immune system can fight HPV infection and it goes away without treatment. For some people, … |
MERCK SHARP & DOHME | 2025-05-13 |
| 123 | Double-blind, Randomized, Placebo-controlled Study Evaluating The Safety and Efficacy of Nipocalimab in Reducing The Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-12 |
| 124 | A Multicenter, Open-Label, Dose Escalation, Phase 1b Study to Evaluate The Safety, Tolerability and Preliminary Efficacy of ASP2016 for Friedreich Ataxia Cardiomyopathy Related Papers Related Patents Related Grants Related Experts Highlight: Friedreich Ataxia is a rare condition that causes damage to the nervous system and muscles. People with Friedreich Ataxia have difficulty walking, lose sensation in their arms and legs, and have slurred speech. It can also affect the heart and many people with Friedrich Ataxia develop serious heart problems. Friedreich Ataxia is a genetic condition which means a faulty gene is passed down through families. This type of gene therapy treats a genetic condition by providing a healthy copy of the gene. At the time this study started, … |
ASTELLAS GENE THERAPIES | 2025-11-28 |
| 125 | A PHASE 1, FIRST IN HUMAN, RANDOMIZED, DOUBLE-BLIND, SPONSOROPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07832837 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms |
PFIZER | 2026-03-13 |
| 126 | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate The Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With A Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age. |
SANOFI PASTEUR A SANOFI COMPANY | 2025-12-03 |
| 127 | Fezolinetant Experience for The Treatment of Vasomotor Symptoms Associated With Menopause Among Women in A German Real-life Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms). Their doctor has decided to give them fezolinetant tablets to help treat these symptoms. Fezolinetant tablets do not contain hormones. Fezolinetant tablets have been approved in some countries to treat hot flashes and night sweats. Doctors have standard clinical practice guidelines to help them decide how to treat women who are going through menopause and have hot flashes and night sweats. The goal of this study is to learn about the value of fezolinetant tablets in treating hot flashes and night sweats that women in Germany experience during menopause. The women that want to take part in the study will take fezolinetant tablets for their hot flashes and night sweats. This study is about collecting information only. The individual’s doctor decides on treatment, not the study sponsor (Astellas). The study will last about 6 months (24 weeks). During the study, the women taking part will complete up to 5 virtual reviews. The virtual reviews will ask the women to complete 3 – 5 surveys. At the first virtual review the women will be asked about their health and other medicines they have taken or are taking. The surveys will ask the women about their hot flashes and night sweats, other menopause symptoms, and how these symptoms affect their health and daily life. After the first or second virtual review the women will take their first dose of fezolinetant tablets and continue taking fezolinetant as explained by their doctor. The women will have 3 virtual follow-up reviews at about 1 week, 3 months (12 weeks), and 6 months (24 weeks) after their first dose of fezolinetant tablets. The women will be asked when they took their fezolinetant tablets or if they stopped taking them. |
ASTELLAS PHARMA EUROPE | 2026-03-06 |
| 128 | A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess The Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; … |
ASHIBIO | 2025-10-14 |
| 129 | A Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate The Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With A Rituximab or A Cyclophosphamide-containing Regimen in Children From 6 Years to < 18 Years of Age With Active ANCA-associated Vasculitis (AAV) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV. |
AMGEN | 2026-03-06 |
| 130 | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA). |
UCB BIOPHARMA SRL | 2026-03-27 |
| 131 | A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma. |
AMGEN | 2026-03-27 |
| 132 | A Multicenter Open-Label, Uncontrolled Study to Evaluate The Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG). |
UCB BIOPHARMA SRL | 2026-03-27 |
| 133 | Evaluation of The Efficacy of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in The Treatment of Cerebral Palsy Due to Brain Hypoxia: A Phase II Randomized Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial aims to evaluate the effectiveness of autologous bone marrow mononuclear cell transfusion in treating cerebral palsy caused by cerebral hypoxia. The key questions the study seeks to answer are: * What is the safety profile in terms of adverse events (AE) and serious adverse events (SAE) observed over the 9 months following the first transplantation? * How does autologous bone marrow mononuclear cell (BM MNC) transplantation impact the gross motor function (GMFM-88) scores and Gross Motor Function Classification System (GMFCS) scores in children with cerebral palsy? * How does autologous BM MNC transplantation influence muscle tone (Modified Ashworth Scale score) and hand motor function (MACS/Mini-MACS scale) in children with cerebral palsy, 9 months post the initial transplantation? Fifty-eight selected patients, aged 1 to 10 years and diagnosed with spastic cerebral palsy due to brain hypoxia, will be randomly divided into two groups: * Group A: will receive two BM MNC infusions with the first at baseline and the second at 6 months ± 21 days (T6) via the spinal route. * Group B: will serve as the control group for the first 9 months. During this period, patients will not receive cell transplantation but will undergo a similar rehabilitation and medication regimen as Group A. After 9 months, Group B will receive two BM MNC infusions: the first at 9 months ± 21 days (T9) and the second at 15 months ± 21 days (T15) via the spinal route, with a follow-up at 18 months ± 21 days (T18) compared to baseline. * Both groups: will undergo rehabilitation for 10 days per month, three times, either at rehabilitation centers or performed by a rehabilitation technician at home. After this period, continued training will be conducted by family members. The combined medication regimen will include muscle relaxants (if muscle spasticity is present), vitamins, and neuroprotective drugs (Piracetam). |
LIEM T NGUYEN; | 2026-01-22 |
| 134 | A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine The Relative Efficacy, Safety, and Immunogenicity of The Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized MRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine. |
VAXART | 2025-10-22 |
| 135 | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels After MRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo. |
MODERNATX | 2026-02-04 |
| 136 | An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006. |
UCB BIOPHARMA SRL | 2026-02-27 |
| 137 | A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate The Safety, Tolerability and Pharmacokinetics of GSK3915393 Administered As A Single Dose to Healthy Participants of Chinese, Japanese and European Ancestry, and to Assess The Effects of GSK3915393, on The Pharmacokinetics of Nintedanib PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: GSK3915393 is a new medicine which is being developed for a chronic lung disease called Idiopathic Pulmonary Fibrosis (IPF). This is a healthy participant study which has two parts. Part A will assess the safety, tolerability, and blood levels of GSK3915393 given as a single dose to healthy participants of Chinese, Japanese, and European ancestries. Part B is a drug-drug interaction (DDI) study that examines the effect of a single dose of GSK3915393 on the blood levels of a single dose of nintedanib, which is an approved drug for IPF. |
GLAXOSMITHKLINE | 2025-02-18 |
| 138 | Exposure to Endocrine Disruptors and Occurrence of Hypospadias: Toxicological, Environmental and Hormonal Imbalance Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to demonstrate the impact of Endocrine-Disrupting Chemicals (EDCs) on the risk of hypospadias incidence. It is a multicenter comparative case-control study, involving two groups. The first group consists of biological mothers who have given birth to children with hypospadias (Case Group), while the second group consists of biological mothers who have given birth to children without any malformations (Control Group). Through an integrative approach that combines a direct toxicological study of numerous pollutants present during pregnancy, and a comprehensive exposome assessment using validated tools, this study can significantly enhance our understanding and prevention of this malformation. |
NICOLAS KALFA; | 2025-11-26 |
| 139 | A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and The Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants. |
GLAXOSMITHKLINE | 2026-02-11 |
| 140 | A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of A Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the immunogenicity and safety of a single dose of investigational RSVPreF3 OA vaccine in Indian older adults 60 years of age (YOA) and above and Indian adults 50-59 YOA at increased risk of RSV-LRTD. |
GLAXOSMITHKLINE | 2025-12-26 |
| 141 | Neurocognitive Disorders in Children with Congenital Heart Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the study is to determine neurological and cognitive disorders in children with congenital heart disease for early diagnosis and treatment |
ZEINAB SALAH MAHMOUD AHMED; | 2025-11-01 |
| 142 | A Single-Centre, Open-Label, Single Sequence Study to Evaluate The Effect of Itraconazole on The Pharmacokinetics of Single Inhaled Doses of GSK3923868 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how itraconazole affects the blood concentration of GSK3923868 in healthy adults. |
GLAXOSMITHKLINE | 2025-03-07 |
| 143 | Post-vaccination Surveillance for Monitoring The Adverse Events Following Immunisation With QDENGA in A Real-world Setting in Malaysia (PRIME-Q) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination. Another aim of this study is to collect the number of persons vaccinated with QDENGA who need to stay in the hospital because of severe dengue fever. No vaccination will be given as part of this study. The study will only collect data of persons already vaccinated with QDENGA who agree to participate. |
ZAMBERI SEKAWI; | 2025-06-12 |
| 144 | A Randomized, Double-Blind Study to Evaluate The Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it. |
MERCK SHARP & DOHME | 2026-01-20 |
| 145 | A Phase 1b Study Evaluating The Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors. |
AMGEN | 2026-03-25 |
| 146 | A Pilot Study of Time-restricted Eating Among Pregnant Females With Severe Obesity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, … |
LISA TUSSING-HUMPHREYS; | 2026-01-23 |
| 147 | An Open-Label, Randomized Study to Evaluate The Relative Bioavailability of A New Tablet Formulation of Minzasolmin and The Potential Effect of Food on The Pharmacokinetics of Minzasolmin in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to estimate the relative bioavailability of a new minzasolmin tablet formulation versus reference ‘granules in capsule’ formulation in healthy participants and to evaluate the effect of food with the new tablet formulation on the pharmacokinetics (PK) of minzasolmin. |
UCB BIOPHARMA SRL | 2025-11-26 |
| 148 | A First-in-Human, Phase 1 Study to Assess The Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of A Single-Induction Dose of ConvertibleCARTM-T Cells Armed With MicAbodyTM Protein (ASP2802) Followed By Maintenance Booster Doses of The MicAbody Protein in Patients With CD20-Positive Relapsed or Refractory B-Cell Lymphomas Related Papers Related Patents Related Grants Related Experts Highlight: CAR-T cell therapy is a type of treatment for people with certain lymphomas. T-cells are white blood cells that help to fight infections. CAR-T cell therapy improves the body’s T-cells to help them better fight cancer cells. ASP2802 is a type of CAR-T cell therapy given with MA-20. MA-20 is a protein that helps the CAR-T cell therapy work inside the body. Before ASP2802 is available as a treatment, … |
ASTELLAS PHARMA GLOBAL DEVELOPMENT | 2025-10-28 |
| 149 | A Phase 3, Multicenter, Open-Label Study to Evaluate The Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times. |
TAKEDA | 2026-01-15 |
| 150 | A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate The Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy (‘AVD’). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; … |
AMARNATH POLISHETTY; | 2026-02-23 |
| 151 | A Multicenter, Open-Label, Outpatient Study to Evaluate The Safe And Effective Use of A Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration By Study Participants With Generalized Myasthenia Gravis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration. |
UCB BIOPHARMA SRL | 2026-03-27 |
| 152 | A Phase III, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate Pharmacokinetics, Safety and Efficacy of ADC189 Tablets/Granules in Children 2-11 Years Old With Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China. This study will test a medicine for influenza in children younger than 5 year of age to see if it is safe and effective. This is a multicenter, randomized, double-blind, controlled Phase III clinical study. The study evaluates the pharmacokinetics, safety and efficacy of ADC189 tablets/granules following a single oral dose in children aged 2 to 11 years with influenza. |
JIAXING ANDICON BIOTECH | 2025-09-23 |
| 153 | An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Assess The Relative Bioavailability of Rocatinlimab (AMG 451) Autoinjector and Vial in Healthy Subjects PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants. |
AMGEN | 2026-01-20 |
| 154 | An Open-Label, Single Center, Randomized, 2-Way Crossover, Single-Dose, Bioequivalence Study of Zilucoplan Injected Subcutaneously Either By A Prefilled Syringe or An Auto-Injector in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the bioequivalence pharmacokinetics, safety, tolerability and device deficiencies of zilucoplan (ZLP) in healthy adult participants |
UCB BIOPHARMA SRL | 2026-01-06 |
| 155 | To Evaluate The Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy, Single Center, Randomized, Open Label, Comparative Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy. The control group will be observed for up to 6months without administration of Telitacicept. This Single center, Randomized, Open Label, Comparative study will evaluate the effect and safety of and Standard treatment for 6months in IgA Nephropathy. |
DONG SUN; | 2025-08-01 |
| 156 | A First-in-Human, Randomized, Investigator-Blind, Participant-Blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB3101 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the safety and tolerability of a single ascending dose of UCB3101 in cohorts of healthy male and female study participants. |
UCB BIOPHARMA SRL | 2025-12-26 |
| 157 | A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate The Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR). |
UCB BIOPHARMA SRL | 2026-02-27 |
| 158 | An Interventional Open-Label, Single-Dose, 4-Treatment, 4-Period Crossover Study to Evaluate The Relative Bioavailability of CTB and AVI Administered Via Various Tablets or Capsule Formulations of PF-07612577 (PF-06264006 [CTB] – PF-07338233 [AVP]) and The Effect of Food on The Bioavailability of CTB and AVI Administered Via Tablets in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about the study medicine CTB-AVP for the treatment of severe urinary tract infections that require hospitalization. This study is seeking for: * adult male and female participants who are healthy and weigh more than 50 kg. * participants who have normal blood pressure, … |
PFIZER | 2025-05-21 |
| 159 | A Phase I/II, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess The Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors. |
JIAN ZHOU; | 2026-01-22 |
| 160 | The Real-World Effectiveness and Safety of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) for Hereditary Angioedema: An Observational Study in China PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema (HAE) attacks in persons of 12 years and older. It has also approved icatibant to treat acute HAE attacks in persons 2 years and older. One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab. The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant. Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab, such as the dose and how often it needs to be given, reasons for stopping the treatment with lanadelumab and how long it was taken until stopping. Participants will be treated by their doctors according to routine medical practice. Only data already available in the medical records of the participants will be reviewed and collected during this study. |
TAKEDA | 2026-01-21 |
| 161 | Paired Non-inferiority Study Comparing Overture Semi-automated Vitrification System (DaVitri) to Standard Manual Process for Clinical Pregnancy Outcomes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will recruit 260 female recipients (and up to a maximum of 130 donors). This study is a sequel to the protocol CP-DV-000-GEN-003, entitled, NON-INFERIORITY STUDY COMPARING OVERTURE SEMI-AUTOMATED VITRIFICATION SYSTEM (DaVitri) TO STANDARD MANUAL PROCESS USING BLASTOCYST RATE AS THE PRIMARY END POINT. Donors will provide informed consent and will be enrolled before egg retrieval. Once the oocytes are retrieved, they will undergo thorough denudation to remove corona cells and will be assessed for maturity. Subsequently, mature MII oocytes exhibiting good morphology, as per the Vienna Consensus, ranging between 12 and 30 in number, … |
OVERTURE LIFE | 2025-08-06 |
| 162 | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS P.G12C Mutation (CodeBreaK 301) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb. |
AMGEN | 2026-04-02 |
| 163 | A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy. |
UCB BIOPHARMA SRL | 2026-03-13 |
| 164 | A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants. |
UCB BIOPHARMA SRL | 2025-11-28 |
| 165 | An Open-Label, Phase 1, Study to Evaluate The Pharmacokinetics, Safety, Tolerability, Pharmacodynamics, and Efficacy of Omaveloxolone in Participants ≥2 to <16 Years of Age With Friedreich's Ataxia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich’s Ataxia (FA) who are at least 16 years old. But, … |
DAVID LYNCH; | 2026-01-07 |
| 166 | A Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate The Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. |
YIMING MU; | 2025-07-28 |
| 167 | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE FORMULATED IN MULTIDOSE VIALS IN HEALTHY FEMALE ADULTS PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies. These antibodies help fight against diseases. This is called an immune response. The purpose of this study is to learn about the safety, tolerability, and immunogenicity of a RSV vaccine called RSVpreF. RSVpreF comes either as: * a single dose in a container (called a vial), … |
PFIZER | 2025-09-25 |
| 168 | Dose-finding for Dobutamine During Transitional Circulation in The Very Preterm Infant PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Single centre, dose finding trial to establish the minimum effective dose of dobutamine required to treat hemodynamic insufficiency, defined as low superior vena cava (SVC) flow, in infants below 33 weeks’ gestation during transitional circulation (first 72 hours from birth). |
INSTITUTO DE INVESTIGACIÓN HOSPITAL UNIVERSITARIO LA PAZ | 2025-03-17 |
| 169 | A Phase 1, Open-label, Single-dose Study to Evaluate The Pharmacokinetics, Safety, and Tolerability of Avacopan in Subjects With Normal Renal Function and Subjects With End-Stage Renal Disease (ESRD) Requiring Hemodialysis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD). |
AMGEN | 2026-03-25 |
| 170 | An Open-label, Single-arm Study Evaluating The Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). |
UCB BIOPHARMA SRL | 2026-03-27 |
| 171 | A Multicenter, Open-label, Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease. |
WENMING CHEN; | 2026-02-05 |
| 172 | A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize The Safety and Immunogenicity of IVX-A12 in Adults 60 Years of Age and Older PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to assess the immunogenicity and safety of IVX-A12 in adults 60 years of age and older. |
ICOSAVAX | 2025-08-26 |
| 173 | An Observational Study Utilising Data From Big MS Data Registries to Evaluate The Long-Term Safety of Vumerity and Tecfidera PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to estimate the incidence rate of serious adverse events (SAEs), including but not limited to malignancies and serious and opportunistic infections, among participants with MS treated with Vumerity, Tecfidera, other selected disease modifying therapies (DMTs \[teriflunomide, beta interferons, or glatiramer acetate\]), or Vumerity after switching from Tecfidera. The secondary objective of the study is to compare the incidence rate of SAEs, including but not limited to malignancies and serious and opportunistic infections, among MS participants treated with Vumerity, Tecfidera, … |
BIOGEN | 2025-10-16 |
| 174 | A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change). |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-13 |
| 175 | A Phase 4, Multicenter, Prospective, Open-Label Study Describing The Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy. |
VISHALA L CHINDALORE; | 2025-11-26 |
| 176 | A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma. |
IMMUNOCORE | 2025-07-24 |
| 177 | Long-Term Extension Study (AtDvance) to Evaluate The Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799). |
GLAXOSMITHKLINE | 2025-11-17 |
| 178 | A Phase 1, Randomized, Open-label, Single Dose, 2-treatment Arm (200 Μg and 800 Μg), 4-way Crossover Study in Healthy Participants Aged 18 to 55 to Compare The Pharmacokinetics of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152A (Test) and HFA-134A (Reference) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to characterize the PK of single doses of salbutamol in healthy participants delivered via an MDI containing propellant HFA-152a (test), and to compare with an MDI containing propellant HFA-134a (reference). |
GLAXOSMITHKLINE | 2026-01-12 |
| 179 | Feasibility and Efficiency of Screening for Neurodevelopmental Disorders By An Advanced Practice Nurse in Children With Congenital Heart Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Feasibility and efficiency of Screening for Neurodevelopmental Disorders by an Advanced Practice Nurse in Children aged 1 to 5 with Congenital Heart Disease |
UNIVERSITY HOSPITAL MONTPELLIER | 2025-09-25 |
| 180 | A Randomized, Double-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics, and The Impact of Food on Pharmacokinetics of HS-10398 in Healthy Participants, and A Clinical Trial to Assess The Pharmacokinetic Characteristics of HS-10398 in Participants With Kidney Dysfunction PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and the impact of food on pharmacokinetics of oral HS-10398 in Chinese healthy participants, and a clinical trial to assess the pharmacokinetic characteristics of oral HS-10398 in Chinese participants with kidney dysfunction |
JIANGSU HANSOH PHARMACEUTICAL | 2025-01-31 |
| 181 | A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate The Immunogenicity and Safety of MRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA). |
GLAXOSMITHKLINE | 2026-03-10 |
| 182 | CAPA-IVM Culture With Low Oxygen Tension PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Capacitation in-vitro maturation (CAPA-IVM) has recently been advanced in culturing oocytes from the germinal vesicle (GV) stage following mild or no controlled ovarian stimulation. Recent research suggested that O2 concentration may significantly regulate oocyte maturation and early embryo development through hypoxia-inducible factor (HIF). Nonetheless, … |
LAN N VUONG; | 2025-06-12 |
| 183 | A Phase 3b, Open-label Study to Evaluate The Non-inferiority of The Immune Response and to Evaluate The Safety of The RSVPreF3 OA Investigational Vaccine in Adults 18-49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults >=60 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above. |
GLAXOSMITHKLINE | 2025-09-25 |
| 184 | Effectiveness of Progestin-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: A Randomized Clinical Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This non-inferiority randomized controlled trial will be conducted at My Duc Hospital, Ho Chi Minh City, Vietnam. This study compares the effectiveness of Progestin-Primed Ovarian stimulation versus GnRH protocol for ovarian stimulation in IVF treatment. Participants will be randomly assigned in a 1:1 ratio to receive Progestins or GnRH antagonists. |
LAN N VUONG; | 2026-03-20 |
| 185 | Efficacy and Safety of The Ton-bridge Carotid Stent for The Treatment of Carotid Artery Stenosis: A Prospective, Multicenter, Non-inferiority, Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this trial is to evaluate effectiveness and safety of the Ton-bridge carotid stent for the treatment of carotid artery stenosis. |
LIQUN JIAO; | 2026-01-02 |
| 186 | A PHASE 1/2, RANDOMIZED, PARTIALLY-BLIND, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE MRNA-BASED INVESTIGATIONAL PANDEMIC H5 INFLUENZA VACCINE CANDIDATE ADMINISTERED IN HEALTHY YOUNGER AND OLDER ADULTS PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age. |
GLAXOSMITHKLINE | 2026-02-05 |
| 187 | An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. The so-called G12D mutation in the KRAS gene is common in people with some solid tumors. ASP4396 is being developed as a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. ASP4396 is not currently available as a treatment for the public. In this study, … |
ASTELLAS PHARMA | 2026-02-02 |
| 188 | Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, MulTi-arm, Multi-staGe, Randomised, GLOBal Adaptive PLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3/MT) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP <130 mmHg), ... |
CRAIG ANDERSON; | 2026-04-01 |
| 189 | A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize The Pharmacokinetics of Three SC Olanzapine Extended-release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine. Another secondary objective is to characterize the pharmacokinetics of ZYPREXA. The planned duration of the study for each participant is 19 weeks. |
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D | 2026-01-26 |
| 190 | A Phase 1, Participant- and Investigator-blinded, Randomized, Single-dose Study to Investigate The Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants. The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either Lebrikizumab or placebo. For each participant, the total duration of the study will be approximately up to 21 weeks, including screening period. |
ELI LILLY | 2025-09-12 |
| 191 | A Multiple-Dose, Open-Label, Randomized, 2-Way Cross-Over Study to Assess The Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV dry syrup after multiple oral doses in healthy male Japanese participants. |
UCB BIOPHARMA SRL | 2025-06-06 |
| 192 | A Phase I/II Trial of Neoadjuvant ADI-PEG 20 in Combination With Ifosfamide and Radiotherapy in Soft Tissue Sarcoma (STS) Related Papers Related Patents Related Grants Related Experts Highlight: In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy. |
MIA WEISS; | 2026-03-17 |
| 193 | A Phase 3, Multicenter, Randomized, Platform Study of P19 Inhibition of The IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn’s Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12. |
JANSSEN RESEARCH & DEVELOPMENT | 2026-03-31 |
| 194 | COMIRNATY Intramuscular Injection for 6 Months to 4 Years Old (Monovalent: Omicron XBB.1.5) Special Investigation for Booster Immunization in Children Aged 6 Months to 4 Years PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice. |
PFIZER | 2025-07-14 |
| 195 | A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate The Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder. |
JIANGSU HANSOH PHARMACEUTICAL | 2025-01-01 |
| 196 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate The Safety, Tolerability, and Immunogenicity of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older Participants (60 to 79 Years Inclusive) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body’s immune system responds by making antibodies after receiving V330. |
MERCK SHARP & DOHME | 2025-11-03 |
| 197 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate The Safety and Efficacy of Fazirsiran in The Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), … |
JUSTIN REYNOLDS; | 2026-03-05 |
| 198 | Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate The Safety and Efficacy of ZM-02 in Retinitis Pigmentosa PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is zM-02’s safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject’s Study Eye. |
WENBIN WEI; | 2026-03-31 |
| 199 | An Open-label Single-arm Clinical Study to Assess The Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders. |
HANSOH BIOMEDICAL R&D COMPANY | 2025-06-25 |
| 200 | The Effectiveness of The Two Different Endometrial Preparation Regimes for Frozen Embryo Transfer in Patients With Adenomyosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF/ICSI. Specifically, it seeks to address the following key questions: 1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI – AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer? 2. What are the common side effects of the GnRHa+AI – … |
LAN N VUONG; | 2026-03-20 |